

Press release 2021-10-05

AcuCort's drug ISICORT® demonstrates a three-year shelf life

AcuCort AB (Spotlight Stock Market: ACUC) today announced that the company's drug ISICORT® has demonstrated a three-year shelf life.

ISICORT® is a thin, fast-dissolving and user-friendly oral film for the treatment of acute and severe allergic reactions, croup in children, chemotherapy-induced nausea and vomiting (CINV) as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. The fast-dissolving oral film contains the glucocorticoid dexamethasone which is a well-known, often used and well-documented anti-inflammatory substance.

"I am very pleased that AcuCort's drug ISICORT® has demonstrated three years of stability data, which means that ISICORT® can withstand at least a three-year shelf life. A confirmed three-year shelf life is a great advantage in the distribution of the drug and ensures the shelf life all the way from production to patient. This is important for a successful commercialization. The preparations for the upcoming commercialization and the work to achieve market approval in more markets are ongoing, as well as our intensive partner dialogues," says Jonas Jönmark, CEO of AcuCort AB.

The information was submitted for publication, through the agency of the contact person below, on October 5, 2021.

For more information, please contact:

Jonas Jönmark, CEO, AcuCort AB

Telephone: + 46 (0)70 365 5400

Email: jonas.jonmark@acucort.se

About AcuCort AB (publ)

AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance – dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). A national application was approved by the Swedish Medical Products Agency (MPA) in October 2020. In February 2021, ISICORT® was granted an additional indication – the treatment of COVID-19 patients who need supplemental oxygen treatment. Altogether, this strengthens the company's assessment that the time to commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit www.acucort.com.